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Objectives: Aspergillus coinfection in coronavirus disease 2019 
patients has rarely been described but may be occurring among coro-
navirus disease 2019 patients admitted to ICUs. Previous reports of 
viral coinfections with Aspergillus, including influenza-associated pul-
monary aspergillosis, suggest that coronavirus disease 2019–associ-
ated aspergillosis is plausible. This report aims to summarize what is 
known about coronavirus disease 2019 complicated by Aspergillus, 
introduces coronavirus disease 2019–associated pulmonary asper-
gillosis as a possible clinical entity, and describes reasons clinical 
suspicion of Aspergillus is warranted in the critical care setting.
Data Sources: We summarize the available evidence suggesting the 
existence of Aspergillus coinfection among severe coronavirus dis-
ease 2019 patients. This includes published coronavirus disease 
2019 patient case series, a case description, and a review of potential 
biologic mechanisms.
Study Selection: Reports of coronavirus disease 2019 patient attri-
butes were selected if they included clinical, microbiologic, or radio-
logic signs of invasive fungal infection.
Data Extraction: Data included in summary tables were identified 
through a literature search for coronavirus disease 2019–associ-
ated pulmonary aspergillosis.
Data Synthesis: We present descriptive data extracted from corona-
virus disease 2019–associated pulmonary aspergillosis case series 
current at the time of article submission.
Discussion: Pulmonary aspergillosis is known to occur among influ-
enza patients requiring intensive care and is associated with increased 
mortality. If Aspergillus coinfections are occurring among coronavirus 
disease 2019 patients, early clinical suspicion and testing are needed 
to understand the epidemiology of these infections and prevent asso-
ciated mortality. As the coronavirus disease 2019 pandemic unfolds, 
reports on the existence of this coinfection are needed, and opportu-
nities to contribute cases of Aspergillus coinfection among coronavi-
rus disease 2019 patients to an ongoing registry are described.
Key Words: aspergillosis; Aspergillus infection; coronavirus; 
coronavirus disease 2019; critical care; viral coinfection
Coinfections with viral and bacterial pathogens are asso-ciated with high mortality among influenza patients and account for an estimated 20–40% of influenza-associated 
deaths (1). Influenza-associated pulmonary aspergillosis (IAPA) 
is an emerging fungal complication of severe influenza, occurring 
in as many as 20% of ICU patients with influenza in some geo-
graphic locations, with high mortality compared with non-IAPA 
ICU influenza patients (51% vs 28%) (2–4). Characteristics of 
IAPA include the absence of conventional risk factors for invasive 
fungal disease (e.g., hematologic malignancy, prolonged neutrope-
nia) and the frequent occurrence of invasive Aspergillus tracheo-
bronchitis. Increased recognition of IAPA has led some centers to 
begin empiric antifungal treatment for some ICU patients with 
this syndrome. Importantly, the clinical and epidemiologic under-
standing of IAPA remains limited and some centers have detected 
much lower rates (6). Recently, an expert opinion, based on a con-
ference report with 29 international experts, was published with 
a proposal for an IAPA case definition (7). This definition might 
further facilitate clinical research and is essential for surveillance.
Whether invasive aspergillosis complicates other severe 
viral respiratory infections, including coronavirus disease 2019 
(COVID-19), in patients without immunosuppression remains 
unknown. One study reported five of 99 patients with confirmed 
COVID-19 treated in Wuhan, China, in January 2020 had posi-
tive fungal cultures or fungal coinfections caused by Aspergillus, 
Candida glabrata, and C. albicans (8). In the same study, 15% of 
patients had antifungal prophylaxis or treatment, suggesting cli-
nician concern for COVID-19 patients’ possibly elevated fun-
gal infection risk. Yang et al (9) reviewed 52 severe COVID-19 
patients, of whom 7 (14%) had additional infections; two of these 
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had Aspergillus (flavus and fumigatus) cultured from respiratory 
specimens, although confirmation of invasive infection was not 
discussed. Radiologic signs characteristic of aspergillosis have also 
been reported. Among 51 confirmed COVID-19 patients, 18% had 
halo sign and 4% had reverse halo sign on CT (10), both of which 
represent clinical factors consistent with but not pathognomonic 
of invasive aspergillosis; mycological evidence was not presented. 
In April 2020, a series of 27 COVID-19 patients with acute respi-
ratory distress syndrome (ARDS) requiring ICU admission and 
mechanical ventilation included nine patients (33%) with putative 
invasive pulmonary aspergillosis, having one or more of the fol-
lowing: positive A. fumigatus culture or quantitative polymerase 
chain reaction (PCR) result, or positive galactomannan and beta-
d-glucan tests in serum or bronchoalveolar lavage (BAL). Six of 
nine met at least two of these criteria and one received antifungal 
treatment (11). Since this case series was published, four addi-
tional case series describing invasive aspergillosis among COVID-
19 ICU patients (n = 35 among all five case series) revealed several 
common features among these patients (Table  1) (11–15). All 
had culture, serologic, or molecular evidence of Aspergillus, and 
hypertension, renal failure or replacement therapy, and abnormal 
chest radiology were common. Importantly, 18 of 35 received cor-
ticosteroids (51%) and 19 of 27 (70%) with reported medications 
received mold-active antifungal treatment. Given corticosteroids 
are a known risk factor for pulmonary aspergillosis among ICU 
patients (16), patients receiving these and antifungal treatment are 
likely to have had true invasive disease.
Although invasive aspergillosis was defined differently in each 
case series, severe COVID-19 (i.e., intensive care or ARDS) was 
common to all. ARDS develops in 15–30% of COVID-19 patients 
(17) and is also associated with development of invasive aspergil-
losis in the ICU. In a cohort of 423 non-COVID ARDS patients, 
8% had Aspergillus-positive respiratory specimens (18). Similarly, 
19% of ICU patients with influenza pneumonia and ARDS devel-
oped invasive aspergillosis (2). ARDS also occurs among invasive 
aspergillosis patients: a single-center study of 83 ICU patients 
with probable invasive aspergillosis found that 14% had radio-
logic signs of ARDS (19). That ARDS is an important feature of 
severe COVID-19 and influenza as well as invasive aspergillosis 
indicates suspicion of aspergillosis is warranted when COVID-
19–associated ARDS is present.
Reports of aspergillosis among severe COVID-19 patients are 
still limited and often do not distinguish between colonization and 
infection. Of note, autopsy studies show that among patients who 
died in the ICU from any cause, invasive aspergillosis is among the 
most commonly missed diagnoses (20). In the setting of the ongo-
ing outbreak of COVID-19 and considering the increased mor-
tality associated with IAPA, aspergillosis coinfection may occur 
among severe COVID-19 patients. We urge clinicians to maintain 
a high index of suspicion for the possibility of this coinfection.
A recent PCR-confirmed COVID-19 case at one author’s insti-
tution suggests that aspergillosis coinfections may exist; similar 
cases at this institution are under investigation. On March 21, 
2020, a 65-year-old man with history of obesity, hypertension, 
intermittent atrial fibrillation, and gout was admitted to a Belgian 
hospital for progressive dyspnea; PCR on a nasopharyngeal swab 
at admission was positive for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), the virus that causes COVID-
19. The patient required increasing oxygen was admitted to the 
ICU on March 22 and was mechanically ventilated on March 23. 
During the following 4 days, the patient developed organ failure 
with refractory hypoxemia requiring extracorporeal membrane 
oxygenation (ECMO) and received piperacillin-tazobactam and 
vancomycin. Six days after ICU admission on March 27, bron-
chial aspirates were taken, revealing piperacillin-tazobactam 
resistant Escherichia coli and A. fumigatus on culture and posi-
tive galactomannan (result value 4.4). Serum galactomannan was 
0.2. These findings prompted meropenem and amphotericin B 
therapy. Repeated positive BAL cultures and galactomannan were 
recorded during April 1–10; the patient was diagnosed with inva-
sive pulmonary aspergillosis in the absence of classical risk factors 
and continued on ECMO as of April 17, 2020.
An elevated risk of pulmonary aspergillosis among COVID-
19 patients is biologically plausible. Like influenza, SARS-CoV-2 
has affinity for pulmonary epithelial cells, and the resulting viral 
binding can lead to alveolar injury and increased pulmonary epi-
thelial and vascular permeability, which could create a permissive 
environment for fungal angioinvasion (21). This mechanism is 
similar to current hypotheses explaining the pathogenesis of IAPA 
(2, 3). Briefly, respiratory epithelial damage and mucociliary clear-
ance dysfunction may potentiate Aspergillus tissue invasion (4). In 
addition, influenza-induced hypoxia and ARDS have been shown 
to attenuate the anti-Aspergillus immune response (22); ARDS 
and hypoxia are frequently reported complications of COVID-
19, especially among ICU-admitted patients. In a report of 138 
COVID-19 patients in Wuhan, China, 26% required ICU admis-
sion and 61% of those developed ARDS; all ICU-admitted patients 
required supplemental oxygen (23). Conceivably, COVID-19–
associated ARDS and hypoxia might also act to attenuate antifun-
gal innate immune responses as in IAPA.
COVID-19 differs from influenza in several ways, which could 
manifest as observed differences between Aspergillus coinfec-
tion in COVID-19 patients and IAPA. Specifically, influenza 
and COVID-19 have different cellular tropisms. SARS-CoV-2 
binds to angiotensin-converting enzyme 2 which is expressed in 
type II pneumocytes and ciliated cells (21). Influenza, includ-
ing H1N1, binds to sialic acids complexed with galactose, 
which are expressed on many more respiratory cells, including 
tracheal and bronchial epithelia (24). It is possible there is no 
association between COVID-19 and pulmonary aspergillosis 
or Aspergillus tracheobronchitis. In addition to epithelial dam-
age, influenza can modulate the immune system by suppress-
ing the nicotinamide adenine dinucleotide phosphate-oxidase 
complex, creating a chronic granulomatous disease (CGD)-like 
state, a condition highly associated with susceptibility to inva-
sive aspergillosis and Staphylococcus aureus infection (25). 
Whether a CGD-like state occurs in COVID-19 remains to 
be elucidated. Therefore, it is important to determine whether 
Aspergillus coinfection occurs and if so, its extent and severity. 
Characterizing such coinfections can advance understanding of 
the mechanisms underlying differential susceptibility to viral-
associated fungal infections.
Importantly, underreporting may be a concern for certain 
fungal infections, including IAPA. In the United States in 2019, 
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only 26% of surveyed infectious disease physicians were familiar 
with the condition and less than 10% reported frequent use of 
Aspergillus galactomannan diagnostic tests among ICU patients 
with influenza (26), likely reflecting the absence of U.S. guidelines 
recommending Aspergillus diagnostics among severe influenza 
patients. For perspective, in a large IAPA study in the Netherlands 
and Belgium where fungal diagnostic testing of ICU influenza 
patients is recommended (5), 46% of 315 immunocompetent ICU 
influenza patients had a BAL fungal culture and 26% had a BAL 
galactomannan test (2). Early diagnosis is key: time from ICU 
admission or influenza diagnosis to IAPA diagnosis can be short 
(3–5 d), with 90-day mortality exceeding 50% (2). Should COVID-
19–associated aspergillosis exist, it will be important to offer cli-
nicians guidance on testing and treatment to optimize clinical 
outcomes and to characterize it clinically and epidemiologically.
Based on what is known of IAPA, testing for Aspergillus coin-
fection would be most appropriate for COVID-19 patients with 
severe pneumonia requiring ICU admission, especially those 
treated with immunomodulatory medication such as corticoste-
roids during the later phase of ARDS. Testing can include fungal 
cultures from BAL or sputum, and BAL and serum Aspergillus 
galactomannan antigen tests, although galactomannan sensi-
tivity and specificity among COVID-19 patients have not been 
characterized. Findings from bronchoscopic visualization, 
biopsy, and autopsy data will be critical in assessing the pres-
ence and anatomic localization of fungal invasion. An important 
challenge in performing such testing in COVID-19 patients is 
that clinicians may wish to avoid aerosol-generating procedures, 
such as BAL, given concern for transmission; recommended 
guidance for healthcare workers on use of personal protective 
equipment should be consulted (27).
Although Aspergillus colonization without infection is possible, 
antifungal treatment should be considered if Aspergillus grows or 
galactomannan is detected in lower respiratory tract specimens, or 
when patients with COVID-19–associated ARDS or sepsis do not 
respond to antibacterial treatment. As manifestations of aspergil-
losis in COVID-19 patients are heterogeneous, ranging from upper 
respiratory tract colonization to acute invasive disease, decisions 
on initiation of antifungal therapy depend on assessment of the 
patients’ condition and mycological evidence supporting inva-
sive infection. Elevated suspicion of Aspergillus coinfection may 
be especially important during the second week of SARS-CoV-2 
infection, as reported median time from onset to severe disease is 
relatively long, about 8 days (8). There is currently no evidence that 
supports antifungal prophylaxis in COVID-19 patients in the ICU.
To facilitate and expedite determination of whether aspergillo-
sis coinfections are occurring in COVID-19 patients, ICU-based 
surveillance and registries are urgently needed. Toward that end, 
the Dutch-Belgian Mycosis Study Group has created a registry 
to report patients admitted to an ICU with suspected or proven 
COVID-19 infection, available to critical care clinicians worldwide 
at https://data.castoredc.com/. Clinicians interested in contribut-
ing cases should ensure compliance with their local institutional 
review board and then contact mycology@radboudumc.nl to be 
added as a registry contributor. Similarly, the U.S.-based Mycosis 
Study Group is developing an ICU-based surveillance network to 
identify and describe COVID-19–associated pulmonary asper-
gillosis (CAPA) coinfections in the United States. Should these 
TABLE 1. Summary of Five Coronavirus Disease 2019–Associated Pulmonary Aspergillosis Case Series
References Country
COVID-19–Associated  






















et al  
(12)
Germany SARS-CoV-2 positive PCR 
with acute respiratory 
distress syndrome 
and IPA by modified 
aspergillus ICU case 
definition algorithm (16) 
5 3 (60) 2 (40) 3 (60) 4 (80) 3 (60) 5 (100) 3 (60)
Alanio  
et al  
(11)
France COVID-19 and ICU 
admission, with IPA by 
MSG/EORTC or modified 
influenza-associated IPA 
criteria
9 7 (78) 1 (11) 2 (29) 4 (44) 6 (67) 2 (22) 4 (44)
van Arkel  
et al  
(13)
Netherlands Laboratory-confirmed 
COVID-19 and ICU 
admission, with  
presumed IPA
6 5 (83) 0 (0) 2 (67) Not  
done
2 (33) 6 (100) 4 (67)
Rutsaert  
et al  
(14)
Belgium COVID-19 and ICU 
admission with invasive 
mechanical ventilation, 
with suspected IPA
7 6 (86) 1 (17) 6 (100) Not  
done
1 (14) 6 (86) 4 (57)
Wang  
et al  
(15)
China SARS-CoV-2 positive PCR 
with proven or probable 
IPA by MSG/EORTC 
criteria










COVID-19 = coronavirus disease 2019, IPA = invasive pulmonary aspergillosis, MSG/EORTC = Mycosis Study Group/European Organization for Research and Treatment of Cancer,  
PCR = polymerase chain reaction, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
aDenominators may vary as some patients did not receive each test.
Beer et al
4 www.ccejournal.org 2020 • Volume 2 • e0211
coinfections be detected and described in the United States, we 
suggest the nomenclature CAPA, which has been established in 
recent case studies (12).
In summary, it is important to consider secondary infections 
as a complication in critically ill COVID-19 patients, including 
whether coinfection with Aspergillus might be occurring without 
classical risk factors for aspergillosis. Critical care staff should 
consider fungal cultures or Aspergillus galactomannan testing in 
COVID-19 patients with severe disease or suspected secondary 
infection that does not respond to antibiotic treatment.
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